Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TIRO-AF: TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

NCT06802081 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.

NCT NCT06802081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06802081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TIRO-AF: TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
Lead sponsor
The Cleveland Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
April 8, 2025
Completion date
June 1, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, obesity